The Monkeypox Virus Antigen Detection Kit Market size was estimated at USD 232.57 million in 2025 and expected to reach USD 252.75 million in 2026, at a CAGR of 8.19% to reach USD 403.76 million by 2032.

Monkeypox, now commonly referred to as mpox, is a zoonotic disease caused by monkeypox virus. Antigen detection kits are designed to identify viral proteins in clinical specimens and can support rapid triage when used with appropriate specimen collection, validated procedures, and confirmatory testing. Their practical value depends on analytical performance, timing of testing, lesion characteristics, and alignment with national guidance. Because symptoms can overlap with other infections, a negative antigen result does not necessarily exclude infection and should be interpreted alongside clinical and epidemiological information.

The diagnostic landscape is being shaped by the need to shorten the interval between suspected infection, isolation advice, clinical management, and public-health response. Laboratory-based nucleic-acid amplification testing remains central in many guidelines, while rapid antigen approaches may complement established workflows when their performance and intended use are clearly defined. Key shifts include greater emphasis on decentralized access, quality-assured specimen collection, infection-prevention procedures, digital result reporting, and referral pathways for confirmatory testing. Regulatory authorization, evidence of clinical performance, and transparent instructions for use remain essential to responsible adoption.

Artificial intelligence can support symptom screening, image-assisted lesion assessment, workflow prioritization, anomaly detection, and aggregation of laboratory and epidemiological data. These applications may help identify cases for testing and improve operational visibility, but they do not independently establish infection. Models require representative, privacy-protected datasets and careful evaluation across skin tones, age groups, disease stages, co-infections, and clinical settings. Human oversight, explainability, cybersecurity, and clear separation between decision support and diagnostic confirmation are necessary, particularly where false positives or false negatives could affect isolation, stigma, or access to care.

North America generally combines established laboratory networks with regulatory pathways for diagnostic products, although access and testing practices can differ by jurisdiction. Latin America benefits from regional public-health cooperation but may face uneven laboratory capacity, procurement constraints, and geographic access challenges. Europe has strong surveillance and laboratory infrastructure, with implementation shaped by national systems and European-level guidance. The Middle East includes highly variable health-system capacity and cross-border movement considerations. Africa requires approaches that strengthen specimen transport, decentralized testing, workforce capability, and integration with broader outbreak surveillance. Asia-Pacific spans advanced diagnostic systems and settings where infrastructure, rural access, and supply continuity remain important determinants of use.

ASEAN members can benefit from interoperable surveillance and shared approaches to cross-border response while accounting for diverse health-system capacity. BRICS members encompass substantial variation in laboratory networks, manufacturing capability, and regulatory practice, making common quality principles valuable even when procurement systems differ. The European Union can leverage coordinated surveillance and regulatory collaboration, while the G7 can support evidence generation, preparedness, and equitable access. GCC states can emphasize coordinated procurement, laboratory readiness, and mobility-related response planning. NATO members may gain from interoperable emergency-health protocols and resilience planning, while maintaining civilian public-health leadership and appropriate data governance.

Australia, Canada, France, Germany, Italy, Japan, South Korea, Spain, the United Kingdom, and the United States generally have established public-health and laboratory systems, but local access, authorization, and referral practices still require attention. Brazil, Mexico, India, China, and Russia represent diverse geographic and institutional settings in which regulatory requirements, domestic capacity, specimen logistics, and regional disparities can strongly influence deployment. Across all listed countries, responsible implementation should align with national guidance, use validated products, protect patient privacy, and link rapid testing with confirmatory laboratory pathways and public-health reporting where required.

Leaders should define the intended-use population and specimen type before deployment, then generate independent clinical evidence across relevant disease stages and care settings. They should establish quality controls, operator training, biosafety procedures, inventory safeguards, and a clear algorithm for confirmatory testing. Partnerships with public-health laboratories and frontline providers can improve usability and surveillance integration, while transparent performance communication can reduce inappropriate reliance on negative results. Investment should also address equitable distribution, multilingual instructions, accessible reporting, cybersecurity, and post-market monitoring for failures, adverse events, and performance variation.

This executive summary uses a qualitative evidence-synthesis approach focused on authoritative public-health guidance, peer-reviewed diagnostic research, regulatory principles, and documented outbreak-response practices. The assessment considers intended use, specimen requirements, analytical and clinical performance, testing workflows, surveillance integration, implementation constraints, and ethical safeguards. Regional, group, and country observations are framed as system-level considerations rather than quantitative rankings. Because recommendations and authorizations can change, users should verify current national guidance, product status, and laboratory protocols before making procurement or clinical decisions.

Monkeypox virus antigen detection kits may offer practical value where rapid, accessible testing supports early triage, but their contribution depends on validated performance and integration with clinical assessment, confirmatory testing, infection prevention, and surveillance. The strongest strategies combine regulatory discipline with equitable access, trained users, reliable supply, and responsible data practices. Artificial intelligence can enhance workflow and surveillance, yet it should remain a support layer rather than a substitute for validated diagnostic methods and expert judgment.